中国神经再生研究(英文版) ›› 2023, Vol. 18 ›› Issue (11): 2395-2396.doi: 10.4103/1673-5374.371362

• 观点:退行性病与再生 • 上一篇    下一篇

人类周细胞降解多种 α-突触核蛋白聚集体

  

  • 出版日期:2023-11-15 发布日期:2023-05-04

Wrapping up the role of pericytes in Parkinson’s disease

Taylor John Stevenson, Birger Victor Dieriks*#br#   

  1. Department of Pharmacology, University of Auckland, Auckland, New Zealand (Stevenson TJ)
    Centre for Brain Research, University of Auckland, Auckland, New Zealand (Stevenson TJ, Dieriks BV) 
    Department of Anatomy and Medical Imaging, University of Auckland, Auckland, New Zealand (Dieriks BV)
  • Online:2023-11-15 Published:2023-05-04
  • Contact: Birger Victor Dieriks, PhD, v.dieriks@auckland.ac.nz.
  • Supported by:
    This work was supported by the Neurological Foundation First Fellowship (2244 FFE) (to TJS); Health Research Council Hercus (21/034), a Neurological Foundation project grant (2026PRG) and the School of Medical Science, University of Auckland (to BVD).

摘要: https://orcid.org/0000-0002-9392-3327 (Birger Victor Dieriks) 

Abstract: Pericytes are classically defined as contractile cells within the central nervous system that regulate blood flow and permeability of the blood-brain barrier (BBB). This one-sided view is gradually changing, and pericytes are now considered versatile cells that can switch their function in response to different stimuli (Uemura et al., 2020). In addition to their role as gatekeepers of the BBB and maintaining homeostasis of the brain’s microenvironment through adjusting the vascular intraluminal diameter, pericytes are both sensors and initiators of inflammation, allowing communication between the cerebral parenchyma and the peripheral system (Dieriks et al., 2022). Pericytes can react quickly by releasing neurotrophins to promote neuroprotection or by secreting pro-inflammatory cytokines, which can exacerbate brain and BBB damage (Dieriks et al., 2022). BBB disruption, blood vessel alterations, and cerebral blood flow abnormalities are commonly seen in neurodegenerative disorders with loss of pericyte coverage present in Parkinson’s disease (PD) and Alzheimer’s disease (Uemura et al., 2020, Elabi et al., 2021).